Announcements Trials

Browse Landscape

Phase

Status

Recruiting 58 Active not recruiting 47 Completed 43 Not yet recruiting 24 Terminated 5 Withdrawn 3 Enrolling by invitation 2 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 34 Magnetic Resonance Spectroscopy 22 Biopsy 20 Cyclophosphamide 11 venetoclax 7 Nivolumab 6 Azacitidine 6 pembrolizumab 5 Etoposide 5 Cisplatin 5 Bevacizumab 5 fludarabine phosphate 4 fludarabine 4 Vincristine 4 Taxes 4 Surgical Procedures, Operative 4 Radiotherapy, Intensity-Modulated 4 Radiosurgery 4 Radiation 4 Doxorubicin 4 Cetuximab 4 durvalumab 3 decitabine and cedazuridine drug combination 3 X-Rays 3 Tacrolimus 3 Surveys and Questionnaires 3 Prednisone 3 Platinum 3 Leucovorin 3 Irinotecan 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × lenvatinib × 1 year × Clear all

NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡